Key Insights

Highlights

Success Rate

33% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

8.3%

2 terminated out of 24 trials

Success Rate

33.3%

-53.3% vs benchmark

Late-Stage Pipeline

8%

2 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed with results

Key Signals

2 with results33% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (3)
P 1 (3)
P 2 (11)
P 3 (2)

Trial Status

Not Yet Recruiting6
Recruiting5
Unknown5
Active Not Recruiting4
Terminated2
Enrolling By Invitation1

Trial Success Rate

33.3%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (24)

Showing 20 of 20 trials
NCT07830511Phase 3Not Yet Recruiting

RIsk aDapted Stereotactic Radiotherapy vs. standarD of Care Radiotherapy in Patients With Prostate Cancer in the Adjuvant or saLvage sEtting With or Without Lymph Node Irradiation (RIDDLELN) - A Phase III Trial

NCT07822984Phase 2Not Yet Recruiting

Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy

NCT07779109Not ApplicableRecruitingPrimary

Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for Endometrial Cancer (PURE-cohort)

NCT07579598Phase 2Not Yet Recruiting

ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma

NCT07537777Phase 2Not Yet Recruiting

Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy

NCT07441941Recruiting

Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup

NCT07230080Active Not Recruiting

Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer

NCT06676722Phase 2Recruiting

SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy

NCT04067570Not ApplicableActive Not RecruitingPrimary

Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients With Localized Prostate Cancer

NCT06946420Phase 3Active Not Recruiting

SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy

NCT05344235Recruiting

Observational Study on Extreme Hypofractionation for Localized Prostate Cancer

NCT06722495Not ApplicableNot Yet RecruitingPrimary

Efficacy and Safety of a Third-Course of Neoadjuvant Immunochemotherapy Combined With SBRT in Locally Advanced Head and Neck Squamous Cell Carcinoma Patients With Stable Disease After Two Treatment Courses: A Single-Arm Exploratory Study

NCT06671691Phase 1Enrolling By Invitation

A Phase I Dose-escalation Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Low-risk Breast Cancer Patients: DESERT I Trial

NCT06538935Phase 2Not Yet Recruiting

SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma

NCT04698915Phase 2TerminatedPrimary

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

NCT05817604Active Not Recruiting

Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)

NCT04476797Phase 1TerminatedPrimary

Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC

NCT06219980Phase 2RecruitingPrimary

SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx

NCT04942275Phase 2UnknownPrimary

Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy

NCT04587817Unknown

Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors

Scroll to load more

Research Network

Activity Timeline